Confronto
AOD-9604 vs. Hexarelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Crescita
Crescita
N. CAS
221231-10-3
140703-51-1
Peso molecolare
1815.09 g/mol
887.05 g/mol
Emivita
0.4 h
0.9 h
Sequenza
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-PheHis-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2Meccanismo d'azione
AOD-9604
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
3
4
di cui sull'uomo
2
3
Effetti registrati
3
3
Contraddizioni aperte
1
0
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between AOD-9604 and Hexarelin?
- AOD-9604 is classified as "Crescita", while Hexarelin is classified as "Crescita". AOD-9604: Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Metabolic Pharmaceuticals as an oral obesity therapy; all phase-2 trials missed the primary endpoint. No marketing approval. The Australian TGA Schedule 4 classification is often misunderstood. Hexarelin: Synthetic hexapeptide of the growth-hormone secretagogue (GHRP) family. In the 1990s investigated as an acromegaly diagnostic and for GH deficiency. Not an approved medicine. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, AOD-9604 or Hexarelin?
- The highest available evidence level is "RCT sull'uomo" for AOD-9604 and "Studio sull'uomo" for Hexarelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of AOD-9604 and Hexarelin in Germany and the United States?
- Germania: AOD-9604 — Non approvato, Hexarelin — Non approvato. Stati Uniti: AOD-9604 — Non approvato, Hexarelin — Non approvato. These are factual summaries with source and review date on the individual pages.